STOCK TITAN
  1. Home
  2. Sec-filings
  3. DAWN
  4. [SCHEDULE 13G] Day One Biopharmaceuticals, Inc. SEC Filing

[SCHEDULE 13G] Day One Biopharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock DAWN logo
Day One Biopharmaceuticals, Inc.

NASDAQ:DAWN

DAWN Rankings

#3691 Ranked by Market Cap
N/A Ranked by Dividends

DAWN Latest News

Jun 10, 2025
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
May 6, 2025
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
Apr 22, 2025
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
Feb 25, 2025
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
Feb 11, 2025
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

DAWN Latest SEC Filings

Jul 14, 2025
[Form 4] Day One Biopharmaceuticals, Inc. Insider Trading Activity
Jun 18, 2025
[Form 3] Day One Biopharmaceuticals, Inc. Initial Statement of Beneficial Ownership
Jun 18, 2025
[Form 4] Day One Biopharmaceuticals, Inc. Insider Trading Activity

DAWN Stock Data

709.54M
84.03M
16.97%
94.6%
17.93%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRISBANE